Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society
Data From Broad Clinical Program Show Investigational Erenumab is Effective at Preventing Migraine in Patients Experiencing Four or More Migraine Days a Month
THOUSAND OAKS, Calif., June 8, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society (AHS) held June 8-11 in Boston. These include a new analysis from a pivotal Phase 2 study highlighting the efficacy of erenumab in patients with 15 or more headache days a month (chronic migraine) and a recent history of acute migraine medication overuse. Addit...
Source: Amgen News Release - June 8, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present At The Goldman Sachs 38th Annual Global Healthcare Conference
THOUSAND OAKS, Calif., June 8, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 38th Annual Global Healthcare Conference at 2:40 p.m. PT on Tuesday, June 13, 2017, in Rancho Palos Verdes, Calif. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the potential...
Source: Amgen News Release - June 8, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab
THOUSAND OAKS, Calif., June 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE: AGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the Biologics License Application (BLA) for ABP 215, a biosimilar candidate to Avastin® (bevacizumab), on July 13, 2017.
"Amgen has a long and proud heritage in oncology, and we are committed to providing physicians and patients a range of high quality therapeutic options," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We look forward to di...
Source: Amgen News Release - June 7, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Submits Regulatory Applications For Repatha ® (evolocumab) Cardiovascular Outcomes Data In US And Europe
Applications Based on Data From Repatha Cardiovascular Outcomes Study Showing an Additional Reduction in Heart Attacks, Strokes and Coronary Revascularizations on Top of Optimized Statin Therapy
THOUSAND OAKS, Calif., June 5, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a variation to the marketing authorization to the European Medicines Agency (EMA) for Repatha® (evolocumab), a PCSK9 inhibitor. The regulatory submissions are based on the 27,564-patient Repatha cardiovascular out...
Source: Amgen News Release - June 5, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Presents New Data From Phase 3 XGEVA ® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017
Analysis Demonstrated XGEVA had a Significantly Lower Rate of Renal Adverse Events Compared to Zoledronic Acid
Data Selected for Best of ASCO® Educational Program
THOUSAND OAKS, Calif., June 4, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the XGEVA® (denosumab) Phase 3 '482 study, the largest international multiple myeloma trial ever conducted. The study met its primary endpoint, demonstrating XGEVA is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.14; p=0.01). The analysis d...
Source: Amgen News Release - June 4, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Presents New Phase 2 Data On IMLYGIC ® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017
First Randomized Study to Evaluate the Combination of IMLYGIC, an Oncolytic Viral Therapy, With a Checkpoint Inhibitor
Data Demonstrate IMLYGIC in Combination With YERVOY® (Ipilimumab) Doubled Objective Response Rate in Unresectable Advanced Melanoma
Responses Not Limited to Injected Lesions; 50 Percent or Higher Reduction in Visceral Lesion Size Occurred More Frequently in Patients in the Combination Arm
THOUSAND OAKS, Calif., June 3, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 '264 study that demonstrated IMLYGIC® (talimogene laherparepvec) in combination with the immune...
Source: Amgen News Release - June 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge
Massachusetts Governor Charles Baker and U.S. Senator Edward Markey Join Members of the Life Sciences Community at Newly Expanded Facility in Kendall Square
CAMBRIDGE, Mass., June 2, 2017 /PRNewswire/ -- When Amgen (NASDAQ:AMGN) purchased a vacant parcel of land in the heart of Kendall Square in Cambridge, Mass. 25 years ago, the area was far from the thriving biotechnology hub it has since become. In 2001, Amgen, a biotechnology pioneer, completed construction of an eight-story, 297,000-square-foot facility on the site. Now one of the world's leading independent biotechnology companies, Amgen has expanded its presen...
Source: Amgen News Release - June 2, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY ™ (Romosozumab) In Postmenopausal Women With Osteoporosis
ARCH Study Met Primary and Key Secondary Endpoints by Reducing the Incidence of New Vertebral, Clinical and Non-Vertebral Fractures
Imbalance in Cardiovascular Events Observed as New Safety Signal
THOUSAND OAKS, Calif. and BRUSSELS, May 21, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the EVENITY™* (romosozumab) ARCH study met both primary endpoints and the key secondary endpoint. At the primary analysis, treatment with EVENITY for 12 months followed by alendronate significantly reduced the incidence of new vertebral fractures through 24 months, clinical fractures...
Source: Amgen News Release - May 21, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
